Simvastatin is a specific hydroxymethyl glutaryl coenzyme A reductase inhibitor, which inhibits endogenous cholesterol synthesis. Recent studies have found that simvastatin could promote osteoblasts proliferation and increase bone formation, so the scholars are increasingly concerned about the drug in the application of bone remodeling. There have been a large number of studies demonstrating the bone-promoting effect of local application with different carriers in various animal models. The effect of simvastatin for bone formation in vivo depends on the concentration of local administration, and people have been trying to find a suitable route of administration. The effects of the drug on the bone metabolism and its mechanism, dosage, carrier are summarize
